7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Younes A and Aggarwall BB | Clinical implications of the tumor necrosis factor family in benign and malignant hematologic disorders. | 2003 | Cancer | pmid:12879461 |
Nawroth P et al. | [Osteoporosis and cardiovascular disease--two sides of the same coin?]. | 2003 | Med. Klin. (Munich) | pmid:12928809 |
Padigel UM et al. | TRANCE-RANK costimulation is required for IL-12 production and the initiation of a Th1-type response to Leishmania major infection in CD40L-deficient mice. | 2003 | J. Immunol. | pmid:14607948 |
Terpos E et al. | New insights into the pathophysiology and management of bone disease in multiple myeloma. | 2003 | Br. J. Haematol. | pmid:14632767 |
Ha H et al. | Lipid rafts are important for the association of RANK and TRAF6. | 2003 | Exp. Mol. Med. | pmid:14508068 |
Zhang L et al. | The role of calmodulin in the regulation of osteoclastogenesis. | 2003 | Endocrinology | pmid:12960067 |
Abrahamsen B et al. | Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. | 2003 | Calcif. Tissue Int. | pmid:12384814 |
Chan BY et al. | Effect of anticoagulants and storage temperature on the stability of receptor activator for nuclear factor-kappa B ligand and osteoprotegerin in plasma and serum. | 2003 | Clin. Chem. | pmid:14633883 |
Jung K et al. | Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. | 2003 | J. Urol. | pmid:14634401 |
Ha H et al. | Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. | 2003 | J. Biol. Chem. | pmid:12637570 |
Ritchlin CT et al. | Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. | 2003 | J. Clin. Invest. | pmid:12639988 |
Al-Qawasmi RA et al. | Genetic predisposition to external apical root resorption in orthodontic patients: linkage of chromosome-18 marker. | 2003 | J. Dent. Res. | pmid:12709501 |
Fujita D et al. | Prostaglandin E2 induced the differentiation of osteoclasts in mouse osteoblast-depleted bone marrow cells. | 2003 | Prostaglandins Leukot. Essent. Fatty Acids | pmid:12711253 |
Katavić V et al. | Increased bone mass is a part of the generalized lymphoproliferative disorder phenotype in the mouse. | 2003 | J. Immunol. | pmid:12538719 |
Nishimura K et al. | Effects of irradiation on cementum matrix cytokins function during periodontal regeneration. | 2003 | Hum. Cell | pmid:15147042 |
Choi BK et al. | Induction of osteoclastogenesis and matrix metalloproteinase expression by the lipooligosaccharide of Treponema denticola. | 2003 | Infect. Immun. | pmid:12496170 |
Liu D et al. | Expression of RANKL and OPG mRNA in periodontal disease: possible involvement in bone destruction. | 2003 | Int. J. Mol. Med. | pmid:12469211 |
Crotti TN et al. | Variability of RANKL and osteoprotegerin staining in synovial tissue from patients with active rheumatoid arthritis: quantification using color video image analysis. | 2003 | J. Rheumatol. | pmid:14677171 |
Helfrich MH | Osteoclast diseases. | 2003 | Microsc. Res. Tech. | pmid:12879419 |
Walsh MC and Choi Y | Biology of the TRANCE axis. | 2003 Jun-Aug | Cytokine Growth Factor Rev. | pmid:12787563 |
Smith BB et al. | A toxicity profile of osteoprotegerin in the cynomolgus monkey. | 2003 Sep-Oct | Int. J. Toxicol. | pmid:14555415 |
Ogasawara T et al. | In situ expression of RANKL, RANK, osteoprotegerin and cytokines in osteoclasts of rat periodontal tissue. | 2004 | J. Periodont. Res. | pmid:14687227 |
Blair HC and Athanasou NA | Recent advances in osteoclast biology and pathological bone resorption. | 2004 | Histol. Histopathol. | pmid:14702187 |
Kumamoto H and Ooya K | Expression of parathyroid hormone-related protein (PTHrP), osteoclast differentiation factor (ODF)/receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoclastogenesis inhibitory factor (OCIF)/osteoprotegerin (OPG) in ameloblastomas. | 2004 | J. Oral Pathol. Med. | pmid:14675140 |
Crisafulli A et al. | Effects of the phytoestrogen genistein on the circulating soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin system in early postmenopausal women. | 2004 | J. Clin. Endocrinol. Metab. | pmid:14715848 |
Onyia JE et al. | Novel and selective small molecule stimulators of osteoprotegerin expression inhibit bone resorption. | 2004 | J. Pharmacol. Exp. Ther. | pmid:14718597 |
Smith MD | Comment on review on T cells in bone biology. | 2004 | Rheumatology (Oxford) | pmid:15448222 |
Boabaid F et al. | Leucine-rich amelogenin peptide: a candidate signaling molecule during cementogenesis. | 2004 | J. Periodontol. | pmid:15455742 |
Schett G et al. | Soluble RANKL and risk of nontraumatic fracture. | 2004 | JAMA | pmid:14996780 |
Tsuji K et al. | Periodontal ligament cells under intermittent tensile stress regulate mRNA expression of osteoprotegerin and tissue inhibitor of matrix metalloprotease-1 and -2. | 2004 | J. Bone Miner. Metab. | pmid:14999519 |
Jørgensen HL et al. | Serum osteoprotegerin (OPG) and the A163G polymorphism in the OPG promoter region are related to peripheral measures of bone mass and fracture odds ratios. | 2004 | J. Bone Miner. Metab. | pmid:14999524 |
Kobayashi-Sakamoto M et al. | NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15013432 |
MacQuarrie RA et al. | Wear-particle-induced osteoclast osteolysis: the role of particulates and mechanical strain. | 2004 | J. Biomed. Mater. Res. Part B Appl. Biomater. | pmid:15015218 |
Ishii T et al. | Osteopontin as a positive regulator in the osteoclastogenesis of arthritis. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15033472 |
Suda T and Miyaura C | [Recent advance in basic research for osteoporosis]. | 2004 | Nippon Rinsho | pmid:15035090 |
Matsumoto T | [Recent advances in the regulation of bone remodeling]. | 2004 | Nippon Rinsho | pmid:15035093 |
Okumura S et al. | [Regulatory mechanism of osteoclast differentiation and function]. | 2004 | Nippon Rinsho | pmid:15035103 |
Udagawa N et al. | [Possible role of RANKL in bone resorption]. | 2004 | Nippon Rinsho | pmid:15035104 |
Inoue D | [OPG(osteoprotegerin)/OCIF(osteoclastogenesis inhibitory factor)]. | 2004 | Nippon Rinsho | pmid:15035105 |
Suzuki Y | [Stimulator of bone resorption interleukin-1, interleukin-6 and gp-130 cytokine family]. | 2004 | Nippon Rinsho | pmid:15035106 |
Miyaura C | [LPS]. | 2004 | Nippon Rinsho | pmid:15035108 |
Sattler AM et al. | Novel aspects on RANK ligand and osteoprotegerin in osteoporosis and vascular disease. | 2004 | Calcif. Tissue Int. | pmid:14523602 |
Bergh JJ et al. | Osteoprotegerin expression and secretion are regulated by calcium influx through the L-type voltage-sensitive calcium channel. | 2004 | Endocrinology | pmid:14525906 |
Wise GE et al. | Regulation of secretion of osteoprotegerin in rat dental follicle cells. | 2004 | Eur. J. Oral Sci. | pmid:15458504 |
Dai SM et al. | Interleukin (IL) 18 stimulates osteoclast formation through synovial T cells in rheumatoid arthritis: comparison with IL1 beta and tumour necrosis factor alpha. | 2004 | Ann. Rheum. Dis. | pmid:15479886 |
Wang JC et al. | Osteosclerosis in idiopathic myelofibrosis is related to the overproduction of osteoprotegerin (OPG). | 2004 | Exp. Hematol. | pmid:15504545 |
Fan X et al. | Nitric oxide regulates receptor activator of nuclear factor-kappaB ligand and osteoprotegerin expression in bone marrow stromal cells. | 2004 | Endocrinology | pmid:14563699 |
Kondo T et al. | 1 alpha,25 dihydroxyvitamin D3 rapidly regulates the mouse osteoprotegerin gene through dual pathways. | 2004 | J. Bone Miner. Res. | pmid:15312241 |
Daroszewska A et al. | Susceptibility to Paget's disease of bone is influenced by a common polymorphic variant of osteoprotegerin. | 2004 | J. Bone Miner. Res. | pmid:15312251 |
Liu JM et al. | [The relationships between changes of serum osteoprotegerin, nuclear factor-kappa B ligand receptor activator, and age, menopause, bone biochemical markers and bone mineral densities in women aged 20 - 75]. | 2004 | Zhonghua Nei Ke Za Zhi | pmid:15312444 |
Jacobson A et al. | Vitamin A differentially regulates RANKL and OPG expression in human osteoblasts. | 2004 | Biochem. Biophys. Res. Commun. | pmid:15313187 |
Ishida M and Amano S | Osteocalcin fragment in bone matrix enhances osteoclast maturation at a late stage of osteoclast differentiation. | 2004 | J. Bone Miner. Metab. | pmid:15316862 |
Sato T et al. | Interleukin-11 as an osteoprotegerin-inducing factor in culture medium of blastic cells from a patient with acute megakaryocytic leukemia complicated with osteosclerosis. | 2004 | Am. J. Hematol. | pmid:15307108 |
Giuliani N et al. | New insight in the mechanism of osteoclast activation and formation in multiple myeloma: focus on the receptor activator of NF-kappaB ligand (RANKL). | 2004 | Exp. Hematol. | pmid:15308315 |
Colucci S et al. | T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG/TRAIL interaction. | 2004 | Blood | pmid:15308561 |
Miyazaki T et al. | Changes in receptor activator of nuclear factor-kappaB, and its ligand, osteoprotegerin, bone-type alkaline phosphatase, and tartrate-resistant acid phosphatase in ovariectomized rats. | 2004 | J. Cell. Biochem. | pmid:15372622 |
Jeffcoate W | Vascular calcification and osteolysis in diabetic neuropathy-is RANK-L the missing link? | 2004 | Diabetologia | pmid:15322748 |
Liu Z et al. | Production of recombinant human osteoprotegrin from Trichoplusia ni cells and Bombyx mori larvae. | 2004 | Protein Pept. Lett. | pmid:15327363 |
Politou M et al. | Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). | 2004 | Br. J. Haematol. | pmid:15327520 |
Xiao XH et al. | [Ascorbic acid inhibits the formation and function of osteoclasts from RAW264.7 cells induced by receptor activated nuclear factor kappaB ligand in vitro]. | 2004 | Zhonghua Yi Xue Za Zhi | pmid:15730627 |
Tiranathanagul S et al. | Actinobacillus actinomycetemcomitans lipopolysaccharide activates matrix metalloproteinase-2 and increases receptor activator of nuclear factor-kappaB ligand expression in human periodontal ligament cells. | 2004 | J. Periodontol. | pmid:15732867 |
Bord S et al. | Synthesis of osteoprotegerin and RANKL by megakaryocytes is modulated by oestrogen. | 2004 | Br. J. Haematol. | pmid:15238146 |
Buxton EC et al. | Changes in serum receptor activator of nuclear factor-kappaB ligand, osteoprotegerin, and interleukin-6 levels in patients with glucocorticoid-induced osteoporosis treated with human parathyroid hormone (1-34). | 2004 | J. Clin. Endocrinol. Metab. | pmid:15240611 |
Kochanowska I et al. | Influence of osteoprotegerin (OPG) on resorption of heterotopically induced ossicle. | 2004 | Cell Tissue Bank | pmid:15241009 |
Corso A et al. | Osteoprotegerin serum levels in multiple myeloma and MGUS patients compared with age- and sex-matched healthy controls. | 2004 | Leukemia | pmid:15241438 |
Harada M et al. | Concentration of osteoprotegerin (OPG) in peritoneal fluid is increased in women with endometriosis. | 2004 | Hum. Reprod. | pmid:15242994 |
Kang HS et al. | Receptor activator of nuclear factor-kappaB is induced by a rottlerin-sensitive and p38 MAP kinase-dependent pathway during monocyte differentiation. | 2004 | Mol. Cells | pmid:15232218 |
Kazama JJ | Osteoprotegerin and bone mineral metabolism in renal failure. | 2004 | Curr. Opin. Nephrol. Hypertens. | pmid:15199291 |
Walsh NC and Gravallese EM | Bone loss in inflammatory arthritis: mechanisms and treatment strategies. | 2004 | Curr Opin Rheumatol | pmid:15201606 |
Terpos E et al. | Autologous stem cell transplantation normalizes abnormal bone remodeling and sRANKL/osteoprotegerin ratio in patients with multiple myeloma. | 2004 | Leukemia | pmid:15215875 |
Brändström H et al. | A single nucleotide polymorphism in the promoter region of the osteoprotegerin gene is related to intima-media thickness of the carotid artery in hypertensive patients. The Swedish Irbesartan Left Ventricular Hypertrophy Investigation vs Atenolol (SILVHIA). | 2004 | Blood Press. | pmid:15223723 |
Wilson SE et al. | RANK, RANKL, OPG, and M-CSF expression in stromal cells during corneal wound healing. | 2004 | Invest. Ophthalmol. Vis. Sci. | pmid:15223796 |
Pioletti DP and Kottelat A | The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts. | 2004 | Biomaterials | pmid:15172492 |
Livshits G et al. | Genetic influences on the circulating cytokines involved in osteoclastogenesis. | 2004 | J. Med. Genet. | pmid:15173242 |
Ueland T et al. | Prognostic value of osteoprotegerin in heart failure after acute myocardial infarction. | 2004 | J. Am. Coll. Cardiol. | pmid:15542278 |
Demer LL and Abedin M | Skeleton key to vascular disease. | 2004 | J. Am. Coll. Cardiol. | pmid:15542279 |
Vidal K et al. | Osteoprotegerin production by human intestinal epithelial cells: a potential regulator of mucosal immune responses. | 2004 | Am. J. Physiol. Gastrointest. Liver Physiol. | pmid:15521102 |
Lee CK et al. | Effects of disease-modifying antirheumatic drugs and antiinflammatory cytokines on human osteoclastogenesis through interaction with receptor activator of nuclear factor kappaB, osteoprotegerin, and receptor activator of nuclear factor kappaB ligand. | 2004 | Arthritis Rheum. | pmid:15593184 |
Grzegorzewska AE and MÅ‚ot M | Ratio of cyclase activating and cyclase inactive parathormone (CAP/CIP) in dialysis patients: correlations with other markers of bone disease. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631341 |
Grzegorzewska AE and MÅ‚ot M | Serum osteoprotegerin level is lower in peritoneal dialysis patients than in hemodialysis ones. | 2004 | Rocz. Akad. Med. Bialymst. | pmid:15631342 |
Yeung RS | The osteoprotegerin/osteoprotegerin ligand family: role in inflammation and bone loss. | 2004 | J. Rheumatol. | pmid:15124240 |
Masi L et al. | Osteoprotegerin (OPG)/RANK-L system in juvenile idiopathic arthritis: is there a potential modulating role for OPG/RANK-L in bone injury? | 2004 | J. Rheumatol. | pmid:15124262 |
Eaton CL et al. | Serum osteoprotegerin (OPG) levels are associated with disease progression and response to androgen ablation in patients with prostate cancer. | 2004 | Prostate | pmid:15042606 |
Nitta K et al. | Serum osteoprotegerin levels and the extent of vascular calcification in haemodialysis patients. | 2004 | Nephrol. Dial. Transplant. | pmid:15128884 |
O' Gradaigh D et al. | Joint erosion in rheumatoid arthritis: interactions between tumour necrosis factor alpha, interleukin 1, and receptor activator of nuclear factor kappaB ligand (RANKL) regulate osteoclasts. | 2004 | Ann. Rheum. Dis. | pmid:15020327 |
Milstead JR et al. | Spaceflight and hindlimb suspension disuse models in mice. | 2004 | Biomed Sci Instrum | pmid:15133943 |
Karst M et al. | Roles of stromal cell RANKL, OPG, and M-CSF expression in biphasic TGF-beta regulation of osteoclast differentiation. | 2004 | J. Cell. Physiol. | pmid:15137062 |
Emanuele E et al. | Plasma osteoprotegerin as a biochemical marker for vascular dementia and Alzheimer's disease. | 2004 | Int. J. Mol. Med. | pmid:15138623 |
Kyrtsonis MC et al. | Serum syndecan-1, basic fibroblast growth factor and osteoprotegerin in myeloma patients at diagnosis and during the course of the disease. | 2004 | Eur. J. Haematol. | pmid:15089762 |
Miao D et al. | Parathyroid hormone-related peptide is required for increased trabecular bone volume in parathyroid hormone-null mice. | 2004 | Endocrinology | pmid:15090463 |
Haynes DR et al. | Regulation of osteoclast activity in peri-implant tissues. | 2004 | Biomaterials | pmid:15109848 |
Ito S and Hata T | Crystal structure of RANK ligand involved in bone metabolism. | 2004 | Vitam. Horm. | pmid:15110169 |
Hao C et al. | Modulation of TRAIL signaling complex. | 2004 | Vitam. Horm. | pmid:15110173 |
Herrmann M and Herrmann W | The assessment of bone metabolism in female elite endurance athletes by biochemical bone markers. | 2004 | Clin. Chem. Lab. Med. | pmid:15576300 |
Jono S | [Risk factors of atherosclerosis in end-stage renal disease patients]. | 2004 | Clin Calcium | pmid:15576949 |
Shimizu M and Tamura T | [Regulation of bone mineralization by parathyroid hormone]. | 2004 | Clin Calcium | pmid:15577058 |
Ogata H et al. | [Prophylaxis and treatment of adynamic bone]. | 2004 | Clin Calcium | pmid:15577107 |
Altun A et al. | Decreased serum osteoprotegerin levels in patients with cardiac syndrome X. | 2004 | J. Endocrinol. Invest. | pmid:15648548 |
Buzi F et al. | Serum osteoprotegerin and receptor activator of nuclear factors kB (RANKL) concentrations in normal children and in children with pubertal precocity, Turner's syndrome and rheumatoid arthritis. | 2004 | Clin. Endocrinol. (Oxf) | pmid:14678293 |
Cheng X et al. | Disabling of receptor activator of nuclear factor-kappaB (RANK) receptor complex by novel osteoprotegerin-like peptidomimetics restores bone loss in vivo. | 2004 | J. Biol. Chem. | pmid:14679212 |